Citigroup lowers its rating on Masimo Corporation MASI to Sell from Neutral and lowers its price target to $20 from $21 on utilization challenges.
Citigroup says, "2012 is unlikely to get easier for MASI after a tough 2011 where
we saw further margin erosion and limited technology adoption among hospital
customers. Software updates and the Pronto-7 re-launch also won't fix larger
headwinds tied to reprocessed sensors and difficult admission trends for the core
pulse-oximetry business."
MASI closed at $21.81 a share on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetReiterationIntraday UpdateAnalyst RatingsCitigroupHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in